| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | +108.4% | -78.9% |
| R&D Expense | $21.6M | +39.6% | +43.4% |
| SG&A Expense | $12.2M | +58.6% | +32.5% |
| Operating Income | -$6.7M | +70.7% | +62.5% |
| Net Income | -$5.5M | +73.6% | +64.0% |
| EPS (Basic) | -$0.82 | +73.7% | -256.5% |
| EPS (Diluted) | -$0.82 | +73.7% | -256.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $21.9M | -55.3% | +1.3% |
| Short-term Investments | $67.7M | -26.6% | -58.5% |
| Accounts Receivable | $391K | +52.7% | -82.3% |
| Current Assets | $93.5M | -35.8% | -51.1% |
| Total Assets | $121.9M | -32.1% | -51.0% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$97.9M | — | — |
| Capital Expenditures | $705K | — | — |
| Investing Cash Flow | $43.4M | — | — |
| Financing Cash Flow | $71K | — | — |
| Free Cash Flow | -$98.6M | — | — |
| $21.0M |
| +8.6% |
| -30.3% |
| Total Liabilities | $71.3M | -43.1% | -50.6% |
| Stockholders' Equity | $50.6M | -6.5% | -51.6% |